ALX Oncology (NASDAQ:ALXO) Downgraded to “Hold” at Lifesci Capital

Lifesci Capital lowered shares of ALX Oncology (NASDAQ:ALXO) from a strong-buy rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports.

A number of other research analysts have also commented on ALXO. Cantor Fitzgerald reiterated an overweight rating on shares of ALX Oncology in a report on Wednesday, May 29th. HC Wainwright restated a buy rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Thursday. Finally, Stifel Nicolaus lowered their price objective on ALX Oncology from $14.00 to $5.00 and set a hold rating on the stock in a research report on Thursday. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $18.17.

ALX Oncology Stock Up 2.1 %

ALXO opened at $2.86 on Wednesday. The business has a 50 day moving average price of $7.25 and a 200 day moving average price of $11.82. ALX Oncology has a twelve month low of $2.51 and a twelve month high of $17.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.21 and a current ratio of 5.21. The firm has a market cap of $149.01 million, a P/E ratio of -0.77 and a beta of 1.06.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.16. Research analysts forecast that ALX Oncology will post -2.89 EPS for the current year.

Insider Buying and Selling at ALX Oncology

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the company’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $15.92, for a total value of $318,400.00. Following the sale, the insider now directly owns 604,205 shares in the company, valued at $9,618,943.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other ALX Oncology news, insider Sophia Randolph sold 12,000 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $15.94, for a total value of $191,280.00. Following the sale, the insider now directly owns 330,349 shares in the company, valued at $5,265,763.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $15.92, for a total value of $318,400.00. Following the sale, the insider now owns 604,205 shares in the company, valued at approximately $9,618,943.60. The disclosure for this sale can be found here. Insiders have sold 78,469 shares of company stock worth $873,346 over the last three months. Company insiders own 33.40% of the company’s stock.

Institutional Trading of ALX Oncology

Several large investors have recently made changes to their positions in ALXO. SG Americas Securities LLC grew its holdings in shares of ALX Oncology by 201.4% during the fourth quarter. SG Americas Securities LLC now owns 30,348 shares of the company’s stock worth $452,000 after purchasing an additional 20,279 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after purchasing an additional 4,706 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of ALX Oncology during the fourth quarter worth $28,000. abrdn plc bought a new stake in shares of ALX Oncology during the fourth quarter worth $986,000. Finally, Jump Financial LLC bought a new stake in shares of ALX Oncology during the fourth quarter worth $371,000. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.